Home
/ Idorsia
/ Competitors

Idorsia Competitors and Similar CompaniesClear all

Idorsia's competitors and similar companies include Novartis, Pfizer, Ipsen, Regeneron Pharmaceuticals, Vifor Pharma and Roivant Sciences.

	Idorsia Idorsia, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs.	Novartis Novartis is a company that researches, develops, manufactures, and markets healthcare products.	Pfizer Pfizer is a research-based biopharmaceutical company engaged in the discovery, development, manufacture, and distribution of healthcare products.	Ipsen Ipsen SA is a France-based pharmaceutical company that produces a range of various types of drugs.	Regeneron Pharmaceuticals Regeneron Pharmaceuticals is a biopharmaceutical company that develops, manufactures, and markets medicines.	Vifor Pharma Vifor Pharma is a diversified group active throughout the healthcare market which, among other things, develops, manufactures, and markets pharmaceutical products.	Roivant Sciences Roivant Sciences is a company that develops and commercializes medicines.
Founding Date	Founding Date 2017	Founding Date 1996	Founding Date 1849	Founding Date 1929	Founding Date 1988	Founding Date 1927	Founding Date 2014
Type	Type Public	Type Public	Type Public	Type Public	Type Public	Type Public	Type Public
Tags	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech clinical research drug development pharma	Tags Healthcare biotech clinical research drug development pharma	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech clinical research drug development pharma	Tags Manufacturing & Industrial drug development healthtech pharma	Tags Healthcare biotech drug development healthtech pharma
Locations	Locations Allschwil, CH HQ Shanghai, CN Lörrach, DE Chiyoda City, JP	Locations Basel, CH HQ Tirana, AL Buenos Aires, AR Macquarie Park, AU Kundl, AT Unterlangkampfen, AT Wien, AT see more	Locations New York, US HQ Buenos Aires, AR Villa Adelina, AR Bentley, AU Footscray, AU Mulgrave, AU Sydney, AU see more	Locations Boulogne-Billancourt, FR HQ Algiers, DZ South Yarra, AU Wien, AT Merelbeke, BE São Paulo, BR Mississauga, CA see more	Locations Tarrytown, US HQ Mississauga, CA Courbevoie, FR München, DE Bengaluru, IN Dublin, IE Limerick, IE see more	Locations Glattbrugg, CH HQ Buenos Aires, AR Melbourne, AU Melbourne, AU Wien, AT Antwerpen, BE São Paulo, BR see more	Locations London, GB HQ Basel, CH Boston, US New York, US
Employees	Employees 8007% increase	Employees 76,057	Employees 83,0005% increase	Employees 5,325	Employees 13,9264% increase	Employees 2,200	Employees 908
Valuation ($)	Valuation ($) N/A	Valuation ($) N/A	Valuation ($) 163.9 b	Valuation ($) 10.2 b	Valuation ($) 102.2 b	Valuation ($) N/A	Valuation ($) 8.8 b
Financial
Revenue (est.)	Revenue (est.) CHF152.4m (FY, 2023)	Revenue (est.) $54.1b (FY, 2023)	Revenue (est.) $58.5b (FY, 2023)	Revenue (est.) €3.1b (FY, 2023)	Revenue (est.) $13.1b (FY, 2023)	Revenue (est.) CHF1.8b (FY, 2021)	Revenue (est.) $124.8m (FY, 2023)
Cost of goods	Cost of goods CHF7.2m (FY, 2023)	Cost of goods $8.2b (FY, 2023)	Cost of goods $25b (FY, 2023)	Cost of goods €449.1m (FY, 2023)	Cost of goods N/A	Cost of goods CHF498.7m (FY, 2021)	Cost of goods N/A
Gross profit	Gross profit CHF146.4m (FY, 2023)	Gross profit $47.7b (FY, 2023)	Gross profit $33.5b (FY, 2023)	Gross profit €2.9b (FY, 2023)	Gross profit N/A	Gross profit CHF1.3b (FY, 2021)	Gross profit N/A
Net income	Net income (CHF297.9m) (FY, 2023)	Net income $9b (FY, 2023)	Net income $2.2b (FY, 2023)	Net income €652.6m (FY, 2023)	Net income $4b (FY, 2023)	Net income CHF265.4m (FY, 2021)	Net income $4.2b (FY, 2023)
Operating ⚠
Phase I Trials Products	Phase I Trials Products N/A	Phase I Trials Products N/A	Phase I Trials Products 27 (FY, 2021)	Phase I Trials Products N/A	Phase I Trials Products N/A	Phase I Trials Products N/A	Phase I Trials Products 4 (Q2, 2021)
Phase II Trials Products	Phase II Trials Products N/A	Phase II Trials Products N/A	Phase II Trials Products 25 (FY, 2021)	Phase II Trials Products N/A	Phase II Trials Products N/A	Phase II Trials Products N/A	Phase II Trials Products 5 (Q2, 2021)
Phase III Trials Products	Phase III Trials Products N/A	Phase III Trials Products 44 (FY, 2022)	Phase III Trials Products 27 (FY, 2021)	Phase III Trials Products N/A	Phase III Trials Products N/A	Phase III Trials Products N/A	Phase III Trials Products 1 (Q2, 2021)
Registration Phase Products	Registration Phase Products N/A	Registration Phase Products 8 (FY, 2022)	Registration Phase Products 10 (FY, 2021)	Registration Phase Products N/A	Registration Phase Products N/A	Registration Phase Products N/A	Registration Phase Products 1 (Q2, 2021)
Funding
Total funding raised	Total funding raised N/A	Total funding raised $ 6.5m	Total funding raised N/A	Total funding raised N/A	Total funding raised $ 53.9m	Total funding raised N/A	Total funding raised $ 1.9b